Literature DB >> 15211700

Respiratory morbidity 20 years after RSV infection in infancy.

M Korppi1, E Piippo-Savolainen, K Korhonen, S Remes.   

Abstract

Epidemiological data suggest that respiratory syncytial virus (RSV) infection in early life is a risk factor for later asthma. There are no prospective studies on RSV infection starting from infancy progressing through childhood into adulthood. We followed up a cohort of children, hospitalized for RSV bronchiolitis or RSV pneumonia before age 24 months, until age 18-20 years. The aim of the study was to evaluate early RSV infection as a risk factor for asthma, bronchial reactivity, and lung function abnormalities in young adults. The participants filled in a questionnaire on asthma and asthma-like symptoms. The clinical study included flow-volume spirometry (FVS), methacholine inhalation challenge (MIC), home PEF (peak expiratory flow) monitoring, and skin prick tests (SPT) to common allergens. Asthma was present in 17-22% of 36 index subjects, depending on asthma definition, compared to 11% of 45 controls. Furthermore, FEV% and MEF25 were lower, and MEF50 tended to be lower, in index than in control subjects. One or more abnormal lung function results were found in 16 (44%) index subjects, but only in 5 (11%) controls (P < 0.01). Bronchial reactivity (PD20 <4,900 microg methacholine) was demonstrated in 16 (46%) index subjects and 14 (32%) controls (NS). At least one positive SPT result was present in 21 (60%) index subjects; 6 (29%) had asthma (NS vs. nonatopic index subjects); 13 (62%) had abnormal lung function (P < 0.05); and 14 (67%) had bronchial reactivity (P < 0.01). In the logistic regression adjusted for atopy, as defined by SPT positivity, RSV infection in infancy was an independent risk factor for lung function abnormality (one or more abnormal results in FVS; OR, 5.27; 95% CI, 1.60-17.36), and also for decreased FEV% and MEF50 when these were analyzed separately. However, RSV infection in infancy was not a significant risk factor for asthma or bronchial reactivity. In young adults, lung function abnormalities may be associated with RSV infection which required hospitalization in infancy. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15211700     DOI: 10.1002/ppul.20058

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  43 in total

Review 1.  Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma.

Authors:  Amy S Feldman; Yuan He; Martin L Moore; Marc B Hershenson; Tina V Hartert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-01       Impact factor: 21.405

2.  Respiratory syncytial virus infection in human bone marrow stromal cells.

Authors:  Fariba Rezaee; Laura F Gibson; Debbie Piktel; Sreekumar Othumpangat; Giovanni Piedimonte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-22       Impact factor: 6.914

3.  Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus).

Authors:  Jessica L Grieves; Zhiwei Yin; Russell K Durbin; Joan E Durbin
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

4.  Burden of respiratory syncytial virus infection in young children.

Authors:  Bernhard Resch
Journal:  World J Clin Pediatr       Date:  2012-10-08

Review 5.  Mechanisms how mucosal innate immunity affects progression of allergic airway disease.

Authors:  Allan R Brasier
Journal:  Expert Rev Respir Med       Date:  2019-02-13       Impact factor: 3.772

Review 6.  The role of the respiratory syncytial virus in airway syndromes in childhood.

Authors:  Mark L Everard
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

7.  Risk of current asthma among adult smokers with respiratory syncytial virus illnesses in early life.

Authors:  Nipasiri Voraphani; Debra A Stern; Anne L Wright; Stefano Guerra; Wayne J Morgan; Fernando D Martinez
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

Review 8.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

Review 9.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

10.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.